Compare ENTA & OEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | OEC |
|---|---|---|
| Founded | 1995 | 1862 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.7M | 395.8M |
| IPO Year | 2012 | 2014 |
| Metric | ENTA | OEC |
|---|---|---|
| Price | $13.71 | $5.95 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 4 |
| Target Price | ★ $20.40 | $6.56 |
| AVG Volume (30 Days) | 245.3K | ★ 832.5K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $102,814,000.00 | ★ $1,806,700,000.00 |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | N/A | $2.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $6.44 | $4.35 |
| 52 Week High | $17.15 | $11.60 |
| Indicator | ENTA | OEC |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 41.05 |
| Support Level | $13.19 | $5.21 |
| Resistance Level | $13.97 | $6.58 |
| Average True Range (ATR) | 0.80 | 0.45 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 30.12 | 33.11 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.